60%
Reduction in per-sample cost.
3X
Samples combined per experiment
2
Muliplexing methods available
Why Sample Multiplexing?
Scale single-cell insights without scaling costs
Many researchers rely on conventional techniques like qPCR, flow cytometry, and bulk NGS due to accessibility — but these approaches are laborious, disconnected, and low throughput. Single-cell DNA, RNA, and protein multiomics reveals clonal heterogeneity, mutation co-occurrence, expression, and therapy response, but per-sample costs remain a barrier. Sample multiplexing removes that barrier.
Two Approaches
Two multiplexing methods, one pipeline
Both methods support up to 3 samples per experiment with automatic demultiplexing in the Tapestri Pipeline. Choose the approach that fits your workflow and sample type.
Widely Adopted Method
Antibody hashing
A widely accepted approach in the single-cell community. Leverages hashtag antibody oligo conjugates (AOCs) from BioLegend (part of Revvity), each with a unique barcode to label and distinguish samples before pooling into a single Tapestri run.
Best For:
Single-cell DNA + Protein multiomics. Compatible with TotalSeq-D workflows.
Pipeline:
Tapestri DNA, DNA + Protein, and GE DNA pipelines
Unique to Tapestri
Multiplexing by genotyping
A first-of-its-kind approach exclusive to the Tapestri Platform. Uses the genetic information of relevant variants identified through bulk next-generation sequencing to distinguish samples. No additional labeling reagents required.
Best for: Single-cell DNA sequencing with samples that have known variant profiles from prior bulk NGS — or paired with the Tapestri Bulk NGS Ancillary Kit when bulk data isn't yet available.
Key advantage: No additional reagents or cell-labeling steps required.
Pipeline: Tapestri DNA, DNA + Protein, DNA + RNA pipelines
Method comparison at a glance
Feature | Antibody Hashing | Genotyping |
|---|---|---|
Supported modality | DNA, DNA + Protein | DNA, DNA + Protein, DNA + RNA |
Unique to Tapestri | — No | ✓ Yes |
Additonal reagents | BioLegend AOCs required | None needed |
Prior bulk NGS data required | No | Yes (can be generated with Tapestri Bulk NGS Ancillary Kit) |
Max samples per experiment | Up to 3 | Up to 3 |
Automatic demultiplexing | ✓ Yes — Tapestri Pipeline | ✓ Yes — Tapestri Pipeline |
Pipeline compatibility | DNA, DNA + Protein, GE DNA | DNA, DNA + Protein, DNA + RNA |
Key Benefits
More from every run
A multiplexed Tapestri experiment delivers the same robust single-cell data — at a fraction of the per-sample cost and operational effort.
60%
Lower per-sample cost
Pooling samples reduces hands-on time, reagent usage, and sequencing spend by up to 60% for single-cell DNA and protein multiomics.
3X
Higher throughput
Process multiple samples in a single experiment to enable larger, more statistically robust study designs without proportional cost increases.
Research Applications
Built for high-impact science
Sample multiplexing accelerates the most demanding programs in oncology, genome editing, and cell & gene therapy.
Hematologic Malignancies
Characterize clonal dynamics in AML, CLL, and Multiple Myeloma. Detect rare subclones and track therapy resistance at single-cell resolution.
Cell & Gene Therapy
Multiplex treatment arms and patient samples to fine-tune product characterization. Assess editing efficiency across conditions in one experiment.
CRISPR & base editing
Pool multiple guide conditions. Quantify on-target editing, indel spectra, and HDR efficiency with single-cell precision.
Biomarker Discovery
Process matched patient cohorts together. Reduce inter-run variation and improve statistical power while cutting sequencing costs.
Drug Development
Multiplex treatment arms, timepoints, or patient samples to streamline IND-enabling studies at a fraction of traditional cost.
Clinical Studies
Enable single-cell characterization in preclinical and clinical therapeutic studies. Collect cellular-resolution insights as indicators of target inhibition and efficacy.
“Single-cell characterization in preclinical and clinical therapeutic studies is crucial. Collecting therapeutic effects at the cellular resolution can serve as indicators of successful target inhibition and efficacy in the clinical setting, especially for pediatric cancers and hematological malignancies. Mission Bio's multiplexing capabilities make single-cell technology more accessible to the biomedical community and have the potential to dramatically impact patient care in the future.”
Ilaria Iacobucci, Ph.D.
Ready to Multiplex?
Speak with a Mission Bio scientist to find the right multiplexing approach for your research program.
